Abstract
Introduction
The model provides a comprehensive analysis of the mAb market, forecasting its
commercial evolution out to 2012 and assessing trends by product, company,
therapy area, technology and target type. It also provides an insight into the
direction of mAb technology evolution and an analysis of pipeline dynamics.
Key reasons to read this report
- Assess the key products that will drive sales growth in the mAb market to
2012
- Analyze historical and forecast sales for all mAb products in the
PharmaVitae universe
- Assess all pipeline mAbs currently in development from pre-clinical
testing to pre-registration
View Cart
